zhpsЖурнал прикладной спектроскопииZhurnal Prikladnoii Spektroskopii0514-7506B. I. Stepanov Institute of Physics of the National Academy of Scienceszhps-1136Research ArticleСтатьиРАЗРАБОТКА И ВАЛИДАЦИЯ КИНЕТИЧЕСКОГО СПЕКТРОФОТОМЕТРИЧЕСКОГО МЕТОДА ОПРЕДЕЛЕНИЯ ВЕНЛАФАКСИНА ГИДРОХЛОРИДАDEVELOPMENT AND VALIDATION OF KINETIC SPECTROPHOTOMETRIC METHOD FOR DETERMINATION OF VENLAFAXINE HYDROCHLORIDESonyT. H. KumarSonyT. H. Kumar

Siddipet, Telangana

Siddipet, Telangana

hemkar_pharma@yahoo.co.inManjunathS. Y.ManjunathS. Y.

Siddipet, Telangana

Siddipet, Telangana

RasheedS. H.RasheedS. H.

Siddipet, Telangana

Siddipet, Telangana

Department of Pharmaceutical Analysis, Srikrupa Institute of Pharmaceutical ScienceDepartment of Pharmaceutical Analysis, Srikrupa Institute of Pharmaceutical Sciences202226092022895682687Copyright © Sony T., Manjunath S.Y., Rasheed S.H., 20222022Sony T., Manjunath S.Y., Rasheed S.H.Sony T., Manjunath S.Y., Rasheed S.H.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://zhps.ejournal.by/jour/article/view/1136

Для количественного определения венлафаксина гидрохлорида в нерасфасованном виде, а также в фармацевтических препаратах разработан чувствительный и простой кинетический спектрофотометрический метод. Реакция окисления венлафаксина проведена в присутствии щелочного перманганата калия в качестве окислителя и гидроксида натрия в качестве основной среды при комнатной температуре. Из-за образования манганаинового иона спектрофотометрическое измерение проводили на длине волны 610 нм. Для построения калибровочных кривых использован метод фиксированного времени (15 мин). Метод оптимизирован для всех условий проведения реакции, диапазон линейности 5–30 мкг/мл, предел обнаружения 0.07 мкг/мл. Разработанный метод успешно применен для количественного определения венлафаксина гидрохлорида в лекарственной форме, процент извлечения 98.87–100.22%. Статистическое сравнение полученных результатов с данными традиционного метода не выявило существенных различий в точности.

A kinetic spectrophotometric method that is sensitive and simple has been developed for the quantification of the venlafaxine hydrochloride in bulk as well as in pharmaceutical preparations. In this technique, venlafaxine is oxidized in the presence of alkaline potassium permanganate as an oxidizing agent and sodium hydroxide as a basic medium, and the reaction is carried out at room temperature. Due to the production of a manganate ion, the spectrophotometric measurement was performed at 610 nm. A fixed-time-based approach (15 min) was used to plot calibration graphs. The proposed method was optimized for all the conditions of reaction, whereby the linearity range was found to be 5–30 µg/mL with a limit of detection of 0.07 µg/mL. For the quantification of venlafaxine hydrochloride in a dosage form, the developed method was successfully applied and the percentage recovery was 98.87–100.22%. Statistical comparison was done for the obtained results with those of an official method and no significant differences regarding precision and accuracy were found.

кинетический спектрофотометрический методвенлафаксина гидрохлоридперманганат калияфармацевтические препаратыkinetic spectrophotometric methodvenlafaxine hydrochloridepotassium permanganatepharmaceutical preparationsReferencesK. Ghose, Br. J. Clin. Pharm., 10, 539–550 (1980).K. Ghose, Br. J. Clin. Pharm., 10, 539–550 (1980).A. T. Harvey, R. L. Rudolph, S. H. Preskorn, Arch. Gen. Psychiatry, 57, 503–509 (2000).A. T. Harvey, R. L. Rudolph, S. H. Preskorn, Arch. Gen. Psychiatry, 57, 503–509 (2000).A. Karani, P. Pingale, J. Pharm. Res., 2, 1246–1249 (2009).A. Karani, P. Pingale, J. Pharm. Res., 2, 1246–1249 (2009).C. Sowmya, Y. P. Reddy, K. M. Kumar, S. M. Raja, Int. J. Chem., 1, 52–58 (2011).C. Sowmya, Y. P. Reddy, K. M. Kumar, S. M. Raja, Int. J. Chem., 1, 52–58 (2011).S. Shahnawaz, Z. Siddiqui, Q. Hoda, J. Fluoresc., 20, 821–825 (2010).S. Shahnawaz, Z. Siddiqui, Q. Hoda, J. Fluoresc., 20, 821–825 (2010).K. Raghubabu, L. S. Swarup, B. Kalyanaramu, M. N. Rao, J. Chem., 9, 1645–1654 (2012).K. Raghubabu, L. S. Swarup, B. Kalyanaramu, M. N. Rao, J. Chem., 9, 1645–1654 (2012).V. Samanidou, C. Nazyropoulou, L. Kovatsi, Bioanalysis, 3, 1713–1718 (2011).V. Samanidou, C. Nazyropoulou, L. Kovatsi, Bioanalysis, 3, 1713–1718 (2011).K. Lavanya, P. Sunitha, A. A. Kumar, K. V. Ramana, Int. J. Pharm. Qual., 4, 1–3 (2013).K. Lavanya, P. Sunitha, A. A. Kumar, K. V. Ramana, Int. J. Pharm. Qual., 4, 1–3 (2013).G. S. Rathore, P. K. Basniwal, M. Suthar, R. N. Gupta, Asian J. Chem., 21, 5908–5910 (2009).G. S. Rathore, P. K. Basniwal, M. Suthar, R. N. Gupta, Asian J. Chem., 21, 5908–5910 (2009).M. M. Eswarudu, V. Anitha, P. S. Babu, J. Pharm. Pharm. Sci., 6, 1292–1300 (2017).M. M. Eswarudu, V. Anitha, P. S. Babu, J. Pharm. Pharm. Sci., 6, 1292–1300 (2017).S. A. Edla, Int. J. Sci. Technol., 1, 11–21 (2012).S. A. Edla, Int. J. Sci. Technol., 1, 11–21 (2012).E. B. Asafu-Adjaye, P. J. Faustino, M. A. Tawakkul, L. W. Anderson, X. Y. Lawrence, H. Kwon, J. Pharm. Biomed. Anal., 43, 1854–1859 (2007).E. B. Asafu-Adjaye, P. J. Faustino, M. A. Tawakkul, L. W. Anderson, X. Y. Lawrence, H. Kwon, J. Pharm. Biomed. Anal., 43, 1854–1859 (2007).S. L. Baldania, K. K. Bhatt, R. S. Mehta, D. A. Shah, R. G. Tejal, Indian J. Pharm. Sci., 70, 124–128 (2008).S. L. Baldania, K. K. Bhatt, R. S. Mehta, D. A. Shah, R. G. Tejal, Indian J. Pharm. Sci., 70, 124–128 (2008).L. S. Bernardi, P. R. Oliveira, F. S. Murakami, S. H. Borgmann, M. Z. Arend, S. G. Cardoso, J. Chromatogr. Sci., 47, 770–776 (2009).L. S. Bernardi, P. R. Oliveira, F. S. Murakami, S. H. Borgmann, M. Z. Arend, S. G. Cardoso, J. Chromatogr. Sci., 47, 770–776 (2009).J. Kaur, K. K. Srinivasan, A. Joseph, A. Gupta, Y. Singh, K. S. Srinivas, J. Pharm. Bioallied Sci., 2, 22–26 (2010).J. Kaur, K. K. Srinivasan, A. Joseph, A. Gupta, Y. Singh, K. S. Srinivas, J. Pharm. Bioallied Sci., 2, 22–26 (2010).S. N. Makhija, P. R. Vavia, J. Pharm. Biomed. Anal., 28, 1055–1059 (2002).S. N. Makhija, P. R. Vavia, J. Pharm. Biomed. Anal., 28, 1055–1059 (2002).Sony, T. H. Kumar, S. Y. Manjunath, Indo Am. J. Pharm. Res., 11, 1517–1524 (2021).Sony, T. H. Kumar, S. Y. Manjunath, Indo Am. J. Pharm. Res., 11, 1517–1524 (2021).S. D. Sheorey, U. D. Vachhani, S. S. Vaghani, A. Pandya, H. Soni, S. Shah, Int. J. Pharm. Chem. Sci., 1, 1951–1959 (2012).S. D. Sheorey, U. D. Vachhani, S. S. Vaghani, A. Pandya, H. Soni, S. Shah, Int. J. Pharm. Chem. Sci., 1, 1951–1959 (2012).H. K. Kang, M. A. Kang, H. J. Kim, Y. S. Park, Y. S. Kim, J. S. Kang, Transl. Clin. Pharm., 22, 35–42 (2014).H. K. Kang, M. A. Kang, H. J. Kim, Y. S. Park, Y. S. Kim, J. S. Kang, Transl. Clin. Pharm., 22, 35–42 (2014).S. K. Dubey, R. N. Saha, H. Jangala, S. Pasha, J. Pharm. Anal., 3, 466–471 (2013).S. K. Dubey, R. N. Saha, H. Jangala, S. Pasha, J. Pharm. Anal., 3, 466–471 (2013).Z. Wei, X. Bing-Ren, W. Cai-Yun, Biomed. Chromatogr., 21, 266–272 (2007).Z. Wei, X. Bing-Ren, W. Cai-Yun, Biomed. Chromatogr., 21, 266–272 (2007).M. Akram, M. El-Didamony, O. Abo-Elsoad Mona, J. Saudi Chem. Soc., 21, 58–66 (2017).M. Akram, M. El-Didamony, O. Abo-Elsoad Mona, J. Saudi Chem. Soc., 21, 58–66 (2017).N. Rahman, Y. Ahmad, S. N. H. Azmi, Eur. J. Pharm. Biopharm., 57, 359–367 (2004).N. Rahman, Y. Ahmad, S. N. H. Azmi, Eur. J. Pharm. Biopharm., 57, 359–367 (2004).L. Kishore, A. Kumar, A. Y. Nair, N. Kaur, J. Mex. Chem. Soc., 56, 355–361 (2012).L. Kishore, A. Kumar, A. Y. Nair, N. Kaur, J. Mex. Chem. Soc., 56, 355–361 (2012).ICH Steering Committee. Proc. Int. Conf. Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, London, UK (1996).ICH Steering Committee. Proc. Int. Conf. Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, London, UK (1996).

The authors declare that there are no conflicts of interest present.